Bupropion and weight loss: does it work?

24 Mar

Bupropion weight loss has become an increasingly sought-after combination in Sweden, driven by reports that this antidepressant can help patients lose weight rather than gain it — something that is otherwise a well-known problem with SSRIs. In Sweden, bupropion is sold under the brand Voxra, and in combination with naltrexone as Mysimba. But how strong is the evidence really? In this article, we analyze the studies behind bupropion, realistic results, side effects and how the preparation compares to GLP-1-based alternatives.

How does bupropion affect body weight?

Bupropion is a norepinephrine and dopamine reuptake inhibitor (NDRI). Unlike SSRIs, which often lead to weight gain via serotonergic effects on appetite and metabolism, bupropion works by increasing norepinephrine and dopamine activity in the brain. These neurotransmitters are linked to reward, motivation and energy expenditure.

The appetite suppressant effect of bupropion is thought to be mainly due to the influence of proopiomelanocortin (POMC) neurons in the hypothalamus. POMC neurons release alpha-MSH, which reduces hunger and increases energy expenditure. Bupropion activates these neurons, but the effect is limited by a built-in brake: POMC neurons simultaneously release beta-endorphin, which via opioid receptors dampens the appetite-inhibiting signal.

This is exactly why the combination bupropion + naltrexone (Mysimba/Contrave) is more effective than bupropion alone. Naltrexone blocks the opioid receptors and removes the “brake” — the POMC neurons can then send their appetite-suppressing signal without adverse feedback. This mechanism explains why bupropion alone produces a modest weight effect, while the combination preparation produces 2–3 times greater results.

Voxra weight loss — what do the studies show about bupropion alone?

Bupropion is not approved for weight loss in Sweden. It is prescribed as an antidepressant (Voxra 150–300 mg) and as a smoking cessation aid (Zyban). Weight loss is a documented “side effect” — not the primary indication.

What results can you expect with bupropion alone?

A meta-analysis published in Obesity Reviews (2016) summarized data from studies using bupropion alone for weight loss. Average weight loss was 2.7 kg more than placebo over 6–12 months. That equates to roughly 2-3% of the body weight of an average participant — modest compared to GLP-1 agonists, but measurable and statistically significant.

The effect was most evident in patients with depression and contemporary obesity. In this group, the weight loss was likely seen as a sum of two effects: reduced emotional overeating as the depression eased, plus bupropion’s direct effect on appetite regulation. Patients without depression who took bupropion for weight loss alone showed weaker results.

Bupropion dosage for weight effect is normally 300 mg daily (extended release), taken as one or two doses depending on the preparation form. Doses below 150 mg rarely produce a measurable effect on weight. Escalation usually occurs over 1–2 weeks from 150 mg to 300 mg, and most patients notice the appetite suppressant effect within 2–3 weeks.

The time profile of weight loss differs from GLP-1 agonists. With bupropion, most occurs in the first 6 months, after which the effect plateaus. Studies that followed patients for 24 months showed that weight loss was maintained but rarely increased after the six-month mark. The combination with naltrexone (Mysimba/Contrave) improves results: the COR-I trial showed 6.1% weight loss over 56 weeks compared to 1.3% for placebo. That’s still modest compared to semaglutide, but not insignificant — for a 95 kg person, that’s just under 6 kg.

An interesting observation from clinical practice: bupropion is particularly effective in patients whose obesity is driven by emotional eating, reward-driven overconsumption and sweet cravings. The dopaminergic mechanism affects precisely the signal systems that control impulsive eating and cravings for sugary foods. Patients with more “metabolically” driven obesity — insulin resistance, high cortisol levels — generally respond less well to bupropion and better to GLP-1 agonists.

Bupropion side effects — what you should know before starting

The side effect profile of bupropion differs markedly from both SSRIs and GLP-1 drugs. The most common side effects in the first few weeks include:

• Dry mouth — reported by 15-25% of users and usually subsides after 2-4 weeks.

• Sleep disorders — insomnia occurs in 10-20%, especially if the second dose is taken too late in the day. The recommendation is not to take bupropion after 16.

• Headache — about 10–15% experience this, most commonly during the first weeks and usually transient.

• Dizziness and tremors — less common (5–8%) but can affect everyday life if it persists.

• Increased blood pressure — bupropion can increase blood pressure by an average of 2-5 mmHg. Patients with hypertension should be monitored regularly.

The most serious risk with bupropion is seizures. The risk is dose-related and is about 0.1% at 300 mg — low in absolute terms, but sufficient to create contraindications. Bupropion should never be given to patients with epilepsy, eating disorders (bulimia or anorexia), alcohol withdrawal or concomitant use of other anticonvulsant drugs.

A positive aspect compared to SSRIs is that bupropion rarely causes sexual dysfunction and does not cause weight gain — two side effects that plague many SSRI users and often lead to treatment discontinuation. This profile makes bupropion a natural first choice for patients with depression who already struggle with obesity and do not want to risk additional pounds from their antidepressant treatment.

Interactions with other drugs should not be underestimated. Bupropion inhibits the enzyme CYP2D6 in the liver, which affects the breakdown of a number of other drugs — including beta blockers (metoprolol), some antipsychotics and codeine. If you take other medications regularly, you should always inform your prescribing doctor before adding bupropion.

Bupropion vs GLP-1 drugs — how do they compare?

The comparison is uneven in terms of pure weight loss. The table below summarizes how bupropion (alone and in combination) stacks up against the most common GLP-1 alternatives:

|Preparation|Average weight loss (1 year)|Main mechanism|Administration|

|Bupropion (Voxra) alone| 2–3 % |NDRI / dopamine+norepinephrine|Tablet, daily|

|Bupropion/naltrexone (Mysimba)| 5–6 % |NDRI + opioid blockade|Tablet, daily|

|Semaglutide (Wegovy)| 14–16 % |GLP-1 agonist|Injection, weekly dosage|

|Tirzepatid (Mounjaro)| 15–21 % |GLP-1/GIP agonist|Injection, weekly dosage|

The numbers speak for themselves: GLP-1 agonists produce 3-5 times greater weight loss. But the pure comparison lacks nuances that often weigh heavily in clinical everyday life.

Bupropion has benefits in specific patient populations. Those suffering from depression and obesity can treat both conditions with a single drug — an advantage that should not be underestimated, as depression often sabotages weight loss efforts. Patients with smoking problems and obesity can benefit from bupropion’s dual effect: smoking cessation plus modest weight loss. Read more about how bupropion stacks up in a broader comparison in our overview of injections vs tablets for weight loss.

The cost also speaks in favor of bupropion. Voxra costs around SEK 200–400 per month with prescription, while Wegovy without subsidy costs SEK 2,000–3,000. For those who do not meet the criteria for subsidized GLP-1 treatment, bupropion can be an economically viable alternative. Mysimba (bupropion/naltrexone) costs approximately SEK 500-700 per month and provides a stronger weight effect than bupropion alone — an intermediate option for those looking for more effect without going all the way to injection-based treatment.

One last aspect that deserves attention: bupropion has a long safety profile with data since 1985. The drug authorities have a good knowledge of the long-term side effects, which provides a security that newer GLP-1 preparations have not yet had time to build. For patients hesitant about relatively new drugs, bupropion’s long clinical history may tip the scales. You can find more options that support weight loss via different mechanisms in our guide to the best fat burners 2026.

.entry-content